3D Medicines Inc.

1244 · HKEX

Public Market Listing

1244HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for 3D Medicines Inc. are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
0Approved
2Phase 3 / Filed
0Phase 1–2 / Early
6Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
PD-L1Monoclonal antibody
HIVNon-Small Cell Lung CancerChronic Hepatitis BEndometrial Cancer
Phase 3
WT1 (Wilms Tumor-1 protein)Vaccine
Acute Myeloid LeukemiaMultiple Myeloma

Upcoming events

(5 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (2)
December 2026 (2)
EnvafolimabPhase 1/2Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
Est. primary completion 2026-12 · NCT05024214 · CT.gov ↗
What to watch
EnvafolimabPhase 2Advanced Endometrial Cancer
Est. primary completion 2026-12 · NCT05112991 · CT.gov ↗
What to watch
2027 (2)
August 2027 (1)
EnvafolimabPhase 2Solid Tumor
Est. primary completion 2027-08-30 · NCT04891198 · CT.gov ↗
What to watch
December 2027 (1)
EnvafolimabPhase 3Non-small Cell Lung Cancer
Est. primary completion 2027-12-30 · NCT06123754 · CT.gov ↗
What to watch
2029 (1)
June 2029 (1)
EnvafolimabPhase 2Biliary Tract Neoplasms
Est. primary completion 2029-06 · NCT04910386 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

17 November 2026Topline resultGalinpepimut-SPhase 3 REGAL topline: overall survival primary endpoint met

Financial reports

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$62M—$61M$6.4Mreport ↗
View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-FY$90M—$94M$19Mreport ↗